Abstract
We measured birth prevalence of major congenital malformations (MCMs) after topiramate use during pregnancy to screen for a possible signal of increased risk. Using four healthcare databases, we identified three cohorts of pregnant women: cohort 1, used topiramate during the first trimester; cohort 2, used topiramate or another antiepileptic drug previously but not during pregnancy; and cohort 3, were pregnant and did not use topiramate but had indications for use individually matched to those of users. Cohort 1 was compared with cohorts 2 and 3. MCMs were a code for any major congenital malformation dated within 30 days of the delivery date on the mother's claims or within 365 days after infant birth date, excluding a genetic or syndromic basis, and with procedure or healthcare usage consistent with the MCM diagnosis code in the 365 days after infant birth. Of the 10 specific common MCMs evaluated, 1 (conotruncal heart defects) had a prevalence ratio greater than 1.5 for both primary comparisons, and 4 (ventricular septal defect, atrial septal defect, hypospadias, coarctation of the aorta) had a prevalence ratio greater than 1.5 for one of the two comparisons. Following screening of organ systems with elevated MCMs, the preval...Continue Reading
References
Jul 23, 2008·Neurology·S HuntUNKNOWN UK Epilepsy and Pregnancy Register
Dec 18, 2008·Birth Defects Research. Part A, Clinical and Molecular Teratology·Janet D Cragan, Suzanne M Gilboa
Sep 25, 2010·Clinical Epidemiology·Jette B KornumMette Nørgaard
Apr 13, 2011·Lancet·Kishore M GaddeWesley W Day
May 19, 2011·JAMA : the Journal of the American Medical Association·Ditte Mølgaard-Nielsen, Anders Hviid
Mar 15, 2012·Seminars in Perinatology·Douglas J Schneider
May 4, 2012·Neurology·S Hernández-DíazUNKNOWN North American AED Pregnancy Registry
Jun 26, 2012·Headache·Mark W GreenArun Bhattacharyya
Jul 4, 2012·Pharmacoepidemiology and Drug Safety·Susan E AndradeWilliam O Cooper
Aug 25, 2012·American Journal of Obstetrics and Gynecology·Andrea V MargulisUNKNOWN National Birth Defects Prevention Study
Dec 1, 2012·Thyroid : Official Journal of the American Thyroid Association·James J KorelitzScott A Rivkees
Mar 7, 2013·Acta Neurologica Scandinavica·F J E VajdaM J Eadie
May 8, 2013·Antimicrobial Agents and Chemotherapy·Anat Bahat DinurAmalia Levy
Feb 4, 2014·PPAR Research·Ying SunTianxin Yang
Apr 3, 2014·Pharmacoepidemiology and Drug Safety·Daniel MinesK Arnold Chan
Citations
Dec 22, 2015·Current Psychiatry Reports·Christina L Wichman
Jun 18, 2016·Reproductive Toxicology·R Bromley
Oct 13, 2016·Expert Opinion on Drug Safety·Bruno Halpern, Marcio C Mancini
Jul 10, 2020·CNS Spectrums·Mikail NourredineBenjamin Rolland
Oct 5, 2016·Experimental and Therapeutic Medicine·Qingmei NieJianping Wei
Jun 14, 2019·Neurology·Pierre-Olivier BlotièreRosemary Dray-Spira
Jan 24, 2021·Birth Defects Research·Thabiso TshabalalaFelix Mbajiorgu
Feb 13, 2021·PloS One·Syed K RafiIrfan Saadi
Feb 17, 2021·CNS Drugs·Mikail NourredineBenjamin Rolland
Sep 10, 2021·Pharmacoepidemiology and Drug Safety·Andrea V MargulisElena Rivero-Ferrer